303 related articles for article (PubMed ID: 28923104)
21. Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer.
Patel MR; Jacobson BA; Ji Y; Drees J; Tang S; Xiong K; Wang H; Prigge JE; Dash AS; Kratzke AK; Mesev E; Etchison R; Federspiel MJ; Russell SJ; Kratzke RA
Oncotarget; 2015 Oct; 6(32):33165-77. PubMed ID: 26431376
[TBL] [Abstract][Full Text] [Related]
22. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
[TBL] [Abstract][Full Text] [Related]
23. Actin-resistant DNAse I Expression From Oncolytic Adenovirus Enadenotucirev Enhances Its Intratumoral Spread and Reduces Tumor Growth.
Tedcastle A; Illingworth S; Brown A; Seymour LW; Fisher KD
Mol Ther; 2016 Apr; 24(4):796-804. PubMed ID: 26708004
[TBL] [Abstract][Full Text] [Related]
24. A Phase I study of KH901, a conditionally replicating granulocyte-macrophage colony-stimulating factor: armed oncolytic adenovirus for the treatment of head and neck cancers.
Chang J; Zhao X; Wu X; Guo Y; Guo H; Cao J; Guo Y; Lou D; Yu D; Li J
Cancer Biol Ther; 2009 Apr; 8(8):676-82. PubMed ID: 19242097
[TBL] [Abstract][Full Text] [Related]
25. Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer.
Park SH; Breitbach CJ; Lee J; Park JO; Lim HY; Kang WK; Moon A; Mun JH; Sommermann EM; Maruri Avidal L; Patt R; Pelusio A; Burke J; Hwang TH; Kirn D; Park YS
Mol Ther; 2015 Sep; 23(9):1532-40. PubMed ID: 26073886
[TBL] [Abstract][Full Text] [Related]
26. Development of a versatile oncolytic virus platform for local intra-tumoural expression of therapeutic transgenes.
Marino N; Illingworth S; Kodialbail P; Patel A; Calderon H; Lear R; Fisher KD; Champion BR; Brown ACN
PLoS One; 2017; 12(5):e0177810. PubMed ID: 28542292
[TBL] [Abstract][Full Text] [Related]
27. Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I/II clinical trial.
Zhang B; Huang J; Tang J; Hu S; Luo S; Luo Z; Zhou F; Tan S; Ying J; Chang Q; Zhang R; Geng C; Wu D; Gu X; Liu B
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33837053
[TBL] [Abstract][Full Text] [Related]
28. First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells.
Minev BR; Lander E; Feller JF; Berman M; Greenwood BM; Minev I; Santidrian AF; Nguyen D; Draganov D; Killinc MO; Vyalkova A; Kesari S; McClay E; Carabulea G; Marincola FM; Butterfield LH; Szalay AA
J Transl Med; 2019 Aug; 17(1):271. PubMed ID: 31426803
[TBL] [Abstract][Full Text] [Related]
29. [YB-1-based virotherapy: A new therapeutic intervention for transitional cell carcinoma of the bladder?].
Holm PS; Retz M; Gschwend JE; Nawroth R
Urologe A; 2016 Mar; 55(3):356-63. PubMed ID: 26556269
[TBL] [Abstract][Full Text] [Related]
30. Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol.
Geletneky K; Huesing J; Rommelaere J; Schlehofer JR; Leuchs B; Dahm M; Krebs O; von Knebel Doeberitz M; Huber B; Hajda J
BMC Cancer; 2012 Mar; 12():99. PubMed ID: 22436661
[TBL] [Abstract][Full Text] [Related]
31. A phase I trial of intratumoral administration of recombinant oncolytic adenovirus overexpressing HSP70 in advanced solid tumor patients.
Li JL; Liu HL; Zhang XR; Xu JP; Hu WK; Liang M; Chen SY; Hu F; Chu DT
Gene Ther; 2009 Mar; 16(3):376-82. PubMed ID: 19092859
[TBL] [Abstract][Full Text] [Related]
32. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial.
Reid T; Galanis E; Abbruzzese J; Sze D; Andrews J; Romel L; Hatfield M; Rubin J; Kirn D
Gene Ther; 2001 Nov; 8(21):1618-26. PubMed ID: 11895000
[TBL] [Abstract][Full Text] [Related]
33. Antagonism of Glycolysis and Reductive Carboxylation of Glutamine Potentiates Activity of Oncolytic Adenoviruses in Cancer Cells.
Dyer A; Schoeps B; Frost S; Jakeman P; Scott EM; Freedman J; Jacobus EJ; Seymour LW
Cancer Res; 2019 Jan; 79(2):331-345. PubMed ID: 30487139
[TBL] [Abstract][Full Text] [Related]
34. Dual but not single PD-1 or TIM-3 blockade enhances oncolytic virotherapy in refractory lung cancer.
Sun F; Guo ZS; Gregory AD; Shapiro SD; Xiao G; Qu Z
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32461344
[TBL] [Abstract][Full Text] [Related]
35. Oncolytic viruses for cancer immunotherapy.
Hemminki O; Dos Santos JM; Hemminki A
J Hematol Oncol; 2020 Jun; 13(1):84. PubMed ID: 32600470
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of oncolytic mutants targeting pRb and p53 pathways is synergistically enhanced when combined with cytotoxic drugs in prostate cancer cells and tumor xenografts.
Radhakrishnan S; Miranda E; Ekblad M; Holford A; Pizarro MT; Lemoine NR; Halldén G
Hum Gene Ther; 2010 Oct; 21(10):1311-25. PubMed ID: 20497039
[TBL] [Abstract][Full Text] [Related]
37. Repurposing Sunitinib with Oncolytic Reovirus as a Novel Immunotherapeutic Strategy for Renal Cell Carcinoma.
Lawson KA; Mostafa AA; Shi ZQ; Spurrell J; Chen W; Kawakami J; Gratton K; Thakur S; Morris DG
Clin Cancer Res; 2016 Dec; 22(23):5839-5850. PubMed ID: 27220962
[TBL] [Abstract][Full Text] [Related]
38. Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial.
Bozorgmehr F; Chung I; Christopoulos P; Krisam J; Schneider MA; Brückner L; Mueller DW; Thomas M; Rieken S
BMC Cancer; 2020 Aug; 20(1):806. PubMed ID: 32842974
[TBL] [Abstract][Full Text] [Related]
39. Replication and virus-induced transcriptome of HAdV-5 in normal host cells versus cancer cells--differences of relevance for adenoviral oncolysis.
Dorer DE; Holtrup F; Fellenberg K; Kaufmann JK; Engelhardt S; Hoheisel JD; Nettelbeck DM
PLoS One; 2011; 6(11):e27934. PubMed ID: 22140489
[TBL] [Abstract][Full Text] [Related]
40. Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination.
Jiang H; Rivera-Molina Y; Gomez-Manzano C; Clise-Dwyer K; Bover L; Vence LM; Yuan Y; Lang FF; Toniatti C; Hossain MB; Fueyo J
Cancer Res; 2017 Jul; 77(14):3894-3907. PubMed ID: 28566332
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
